title: The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?
abstract: In the growing landscape of biomedical public-private-partnerships, particularly for Alzheimer's disease, the question is posed as to their value. What impacts do public-private-partnerships have on clinical and basic science research in Alzheimer's disease? The authors answer the question using the Alzheimer's Disease Neuroimaging Initiative (ADNI) as a test case and example. ADNI is an exemplar of how public-private-partnerships can make an impact not only on clinical and basic science research and practice (including clinical trials), but also of how similar partnerships using ADNI as an example, can be designed to create a maximal impact within their fields.
authors.affiliation: Foundation for the National Institutes of Health, Bethesda, MD, USA. Electronic address: djones-davis@fnih.org.
authors.forename: Dorothy M
authors.initials: DM
authors.lastname: Jones-Davis
authors.affiliation: National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Neil
authors.initials: N
authors.lastname: Buckholtz
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis* / Q000628:therapy*; D035843:Biomedical Research; D002986:Clinical Trials as Topic; D006801:Humans; D059906:Neuroimaging / Q000379:methods*; D055818:Public-Private Sector Partnerships
keywords: ADNI; Alzheimer's disease; Consortia; FNIH; Foundation for the National Institutes of Health; NIA; National Institute on Aging; Public private partnerships